Scarica l'app Stockscreener
1.89
3.08%
-0.06
Dopo l'orario di chiusura:
1.86
-0.03
-1.59%
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché NMRA Giù?
Forum
Previsione
Precedente Chiudi:
$1.95
Aprire:
$1.95
Volume 24 ore:
1.02M
Relative Volume:
1.03
Capitalizzazione di mercato:
$306.08M
Reddito:
-
Utile/perdita netta:
$-274.18M
Rapporto P/E:
-0.7457
EPS:
-2.5346
Flusso di cassa netto:
$-198.33M
1 W Prestazione:
+3.28%
1M Prestazione:
+15.95%
6M Prestazione:
+163.75%
1 anno Prestazione:
-87.73%
Intervallo 1D:
$1.82
$1.98
Intervallo di 1 settimana:
$1.80
$2.02
Portata 52W:
$0.611
$17.19
Neumora Therapeutics Inc Stock (NMRA) Company Profile
Nome
Neumora Therapeutics Inc
Settore
Industria
Telefono
(857) 760-0900
Indirizzo
260 ARSENAL PLACE, SUITE 1, WATERTOWN
Confronta NMRA con altri titoli
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
NMRA
Neumora Therapeutics Inc
|
1.89 | 315.79M | 0 | -274.18M | -198.33M | -2.5346 |
|
VRTX
Vertex Pharmaceuticals Inc
|
407.79 | 106.37B | 11.39B | 3.64B | 3.50B | 13.99 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
460.46 | 59.90B | 2.46B | -319.09M | -52.09M | -2.4669 |
|
REGN
Regeneron Pharmaceuticals Inc
|
564.63 | 60.40B | 14.21B | 4.46B | 3.56B | 39.69 |
|
ARGX
Argen X Se Adr
|
796.92 | 49.56B | 3.06B | 1.28B | 447.35M | 19.67 |
|
ONC
Beone Medicines Ltd Adr
|
320.10 | 36.88B | 4.56B | -176.77M | 225.30M | -1.7177 |
Neumora Therapeutics Inc Stock (NMRA) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2025-09-16 | Downgrade | JP Morgan | Neutral → Underweight |
| 2025-04-02 | Downgrade | BofA Securities | Buy → Underperform |
| 2025-03-10 | Downgrade | William Blair | Outperform → Mkt Perform |
| 2025-03-07 | Downgrade | Guggenheim | Buy → Neutral |
| 2025-03-07 | Downgrade | Stifel | Buy → Hold |
| 2025-01-02 | Downgrade | RBC Capital Mkts | Outperform → Sector Perform |
| 2024-11-05 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-10-01 | Iniziato | H.C. Wainwright | Buy |
| 2024-07-22 | Iniziato | Needham | Buy |
| 2024-07-08 | Iniziato | Mizuho | Outperform |
| 2023-12-12 | Iniziato | Deutsche Bank | Hold |
| 2023-10-10 | Iniziato | BofA Securities | Buy |
| 2023-10-10 | Iniziato | Guggenheim | Buy |
| 2023-10-10 | Iniziato | JP Morgan | Overweight |
| 2023-10-10 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-10-10 | Iniziato | Stifel | Buy |
| 2023-10-10 | Iniziato | William Blair | Outperform |
Mostra tutto
Neumora Therapeutics Inc Borsa (NMRA) Ultime notizie
Using data models to predict Neumora Therapeutics Inc. stock movement2025 Dividend Review & Real-Time Volume Analysis Alerts - newser.com
Will Neumora Therapeutics Inc. see short term momentum2025 Valuation Update & Fast Moving Stock Trade Plans - newser.com
Neumora Therapeutics' (NMRA) Sell (D-) Rating Reaffirmed at Weiss Ratings - MarketBeat
Tools to monitor Neumora Therapeutics Inc. recovery probabilityJobs Report & Community Verified Watchlist Alerts - newser.com
Published on: 2025-10-09 06:47:56 - newser.com
Will Neumora Therapeutics Inc. stock attract more institutional investorsQuarterly Market Summary & Free High Return Stock Watch Alerts - newser.com
Visual analytics tools that track Neumora Therapeutics Inc. performanceTrade Entry Report & High Accuracy Trade Alerts - newser.com
Is Neumora Therapeutics Inc a good long term investmentVolume Weighted Average Price & Rapid Wealth Building Tips - earlytimes.in
Will breakout in Neumora Therapeutics Inc. lead to full recoveryWeekly Profit Report & AI Forecast Swing Trade Picks - newser.com
What insider trading reveals about Neumora Therapeutics Inc. stockQuarterly Market Summary & Stepwise Swing Trade Plans - newser.com
Neumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Rating of "Hold" from Analysts - MarketBeat
Neumora Therapeutics Inc. recovery potential after sell offTrade Volume Report & Weekly Return Optimization Alerts - newser.com
Forecasting Neumora Therapeutics Inc. price range with options dataJuly 2025 PostEarnings & Consistent Return Investment Signals - newser.com
Is Neumora Therapeutics Inc. trending in predictive chart modelsGap Down & Risk Adjusted Buy and Sell Alerts - newser.com
Neumora Therapeutics to Host Virtual R&D Day Highlighting Innovative Therapeutics Pipeline on October 27, 2025 - Quiver Quantitative
Neumora Therapeutics to Host Virtual R&D Day on October 27 - Yahoo Finance
What analysts say about Neumora Therapeutics Inc stockMarket Sentiment Surveys & Start Your Free Trading Journey Today - earlytimes.in
What drives Neumora Therapeutics Inc stock priceEx-Dividend Date Alerts & Minimal Capital Growth Plans - earlytimes.in
Neumora Therapeutics Inc Stock Analysis and ForecastFederal Reserve Announcements & Free Proven Portfolio Growth Strategies - earlytimes.in
Neumora Therapeutics appoints Paul Berns as CEO - MSN
J.P. Morgan Downgrades Neumora Therapeutics(NMRA.US) to Sell Rating - 富途牛牛
Mizuho Raises Price Target for Neumora (NMRA), Keeps Outperform Rating - MSN
Following a 85% Decline Over Last Year, Recent Gains May Please Neumora Therapeutics, Inc. (NASDAQ:NMRA) Institutional Owners - 富途牛牛
3 Promising Penny Stocks With Market Caps At Least $100M - simplywall.st
Aug Reactions: Is Neumora Therapeutics Inc benefiting from innovation trendsLong Setup & Weekly Momentum Stock Picks - خودرو بانک
Neumora Therapeutics (NASDAQ:NMRA) Downgraded by JPMorgan Chase & Co. to Underweight - MarketBeat
Market Pulse: Is Neumora Therapeutics Inc. a stock for growth or value investorsTrade Entry Report & Technical Confirmation Alerts - خودرو بانک
Guidance Update: How liquid is Neumora Therapeutics Inc. stockTrade Signal Summary & Stock Market Timing Techniques - خودرو بانک
Neumora Therapeutics Inc Azioni (NMRA) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Neumora Therapeutics Inc Azioni (NMRA) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| BERNS PAUL L | See Remarks |
Feb 18 '25 |
Sale |
1.69 |
13,871 |
23,468 |
7,405,004 |
| Milligan Michael Lee | See Remarks |
Feb 18 '25 |
Sale |
1.69 |
1,978 |
3,351 |
22,470 |
| Aurora Daljit Singh | Chief Strategy Officer |
Feb 18 '25 |
Sale |
1.68 |
8,565 |
14,347 |
88,935 |
| Lenz Robert A. | Head of R&D |
Feb 18 '25 |
Sale |
1.67 |
5,614 |
9,383 |
309,092 |
| Pinto Joshua | President |
Feb 18 '25 |
Sale |
1.67 |
8,048 |
13,477 |
76,952 |
5.74%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):